Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Azd4877

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07043790Not ApplicableCompletedPrimary

Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma

NCT00661609Phase 2Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Azd48771
  • Trimodal Therapy1
  • Radical Cystectomy With Pelvic Lymphadenectomy1

Active Sponsors

  • AstraZeneca1
  • Ain Shams University1

Top Investigators

Related Conditions

  • Ureter Cancer1
  • Radiation1
  • Cystectomy1
  • Renal Pelvis Cancer1
  • Urethra Cancer1

Activity Timeline